XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Statement of Changes in Stockholders' Equity - USD ($)
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Jun. 30, 2021 $ 372 $ 11,515 $ 144,284,593 $ (114,385,313) $ 29,911,167
Balance (in shares) at Jun. 30, 2021 371,490 11,515,170      
Series A preferred stock issued for employee stock compensation $ 10   32,880   32,890
Series A preferred stock issued for employee stock compensation (in shares) 10,591        
Series A preferred stock issued for license agreement $ 100   934,988   935,088
Series A Preferred stock issued for license agreement (in shares) 100,000        
Common stock issued for consulting and legal services rendered   $ 6 26,994   27,000
Common stock issued for consulting and legal services rendered (in shares)   6,509      
Warrants issued to Scientific Advisory Board     1,352   1,352
Common stock issued for Directors fees   $ 4 14,996   15,000
Common stock issued for Directors fees (in shares)   3,524      
Net loss       (2,613,068) (2,613,068)
Balance at Sep. 30, 2021 $ 482 $ 11,525 145,295,803 (116,998,381) 28,309,429
Balance (in shares) at Sep. 30, 2021 482,081 11,525,203      
Balance at Jun. 30, 2021 $ 372 $ 11,515 144,284,593 (114,385,313) 29,911,167
Balance (in shares) at Jun. 30, 2021 371,490 11,515,170      
Net loss         (6,326,866)
Balance at Mar. 31, 2022 $ 484 $ 11,554 145,457,987 (120,712,179) 24,757,846
Balance (in shares) at Mar. 31, 2022 484,195 11,554,476      
Balance at Sep. 30, 2021 $ 482 $ 11,525 145,295,803 (116,998,381) 28,309,429
Balance (in shares) at Sep. 30, 2021 482,081 11,525,203      
Series A preferred stock issued for employee stock compensation     33,367   33,367
Series A preferred stock issued for employee stock compensation (in shares) 387        
Common stock issued for consulting and legal services rendered   $ 6 26,994   27,000
Common stock issued for consulting and legal services rendered (in shares)   5,993      
Warrants issued to Scientific Advisory Board     1,644   1,644
Common stock issued for Directors fees   $ 3 14,997   15,000
Common stock issued for Directors fees (in shares)   3,288      
Net loss       (1,921,134) (1,921,134)
Balance at Dec. 31, 2021 $ 482 $ 11,534 145,372,805 (118,919,515) 26,465,306
Balance (in shares) at Dec. 31, 2021 482,468 11,534,484      
Series A preferred stock issued for employee stock compensation $ 2   39,399   39,401
Series A preferred stock issued for employee stock compensation (in shares) 1,727        
Common stock issued for consulting and legal services rendered   $ 12 26,988   27,000
Common stock issued for consulting and legal services rendered (in shares)   11,632      
Warrants issued to Scientific Advisory Board     785   785
Common stock issued for employee compensation   $ 3 6,765   6,768
Common stock issued for employee compensation (in shares)   3,572      
Common stock issued for Directors fees   $ 5 11,245   11,250
Common stock issued for Directors fees (in shares)   4,788      
Net loss       (1,792,664) (1,792,664)
Balance at Mar. 31, 2022 $ 484 $ 11,554 145,457,987 (120,712,179) 24,757,846
Balance (in shares) at Mar. 31, 2022 484,195 11,554,476      
Balance at Jun. 30, 2022 $ 485 $ 11,592 145,562,124 (122,492,176) 23,082,025
Balance (in shares) at Jun. 30, 2022 484,582 11,592,173      
Series A preferred stock issued for employee stock compensation $ 10 $ 0 13,854 0 13,864
Series A preferred stock issued for employee stock compensation (in shares) 10,591 0      
Common stock issued for consulting and legal services rendered   $ 13 26,987   27,000
Common stock issued for consulting and legal services rendered (in shares)   12,710      
Warrants issued to Scientific Advisory Board     480   480
Common stock issued for Directors fees   $ 5 11,245   11,250
Common stock issued for Directors fees (in shares)   5,154      
Net loss       (1,570,642) (1,570,642)
Balance at Sep. 30, 2022 $ 495 $ 11,610 145,614,690 (124,062,818) 21,563,977
Balance (in shares) at Sep. 30, 2022 495,173 11,610,037      
Balance at Jun. 30, 2022 $ 485 $ 11,592 145,562,124 (122,492,176) 23,082,025
Balance (in shares) at Jun. 30, 2022 484,582 11,592,173      
Net loss         (5,018,580)
Balance at Mar. 31, 2023 $ 497 $ 11,666 145,726,648 (127,510,756) 18,228,055
Balance (in shares) at Mar. 31, 2023 497,287 11,666,471      
Balance at Sep. 30, 2022 $ 495 $ 11,610 145,614,690 (124,062,818) 21,563,977
Balance (in shares) at Sep. 30, 2022 495,173 11,610,037      
Series A preferred stock issued for employee stock compensation     13,055   13,055
Series A preferred stock issued for employee stock compensation (in shares) 387        
Common stock issued for consulting and legal services rendered   $ 17 26,983   27,000
Common stock issued for consulting and legal services rendered (in shares)   17,366      
Warrants issued to Scientific Advisory Board     223   223
Common stock issued for Directors fees   $ 7 11,243   11,250
Common stock issued for Directors fees (in shares)   7,173      
Net loss       (1,745,134) (1,745,134)
Balance at Dec. 31, 2022 $ 495 $ 11,634 145,666,194 (125,807,952) 19,870,371
Balance (in shares) at Dec. 31, 2022 495,560 11,634,576      
Series A preferred stock issued for employee stock compensation $ 2   17,231   17,233
Series A preferred stock issued for employee stock compensation (in shares) 1,727        
Common stock issued for consulting and legal services rendered   $ 20 26,980   27,000
Common stock issued for consulting and legal services rendered (in shares)   19,983      
Warrants issued to Scientific Advisory Board     183   183
Common stock issued for employee compensation   $ 4 4,818   4,822
Common stock issued for employee compensation (in shares)   3,572      
Common stock issued for Directors fees   $ 8 11,242   11,250
Common stock issued for Directors fees (in shares)   8,340      
Net loss       (1,702,804) (1,702,804)
Balance at Mar. 31, 2023 $ 497 $ 11,666 $ 145,726,648 $ (127,510,756) $ 18,228,055
Balance (in shares) at Mar. 31, 2023 497,287 11,666,471